Literature DB >> 17716332

Should we tolerate tolerability as an objective in early drug development?

A Cohen.   

Abstract

Mesh：

Substances：

Year:  2007        PMID： 17716332      PMCID： PMC2000647          DOI： 10.1111/j.1365-2125.2007.03023.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  24 in total

Review 1.  Joining the DoTS: new approach to classifying adverse drug reactions.

Authors:  J K Aronson; R E Ferner
Journal:  BMJ       Date:  2003-11-22

2.  Cerivastatin monotherapy-induced muscle weakness, rhabdomyolysis and acute renal failure.

Authors:  Rashed Bakri; Joe Wang; Anthony S Wierzbicki; David Goldsmith
Journal:  Int J Cardiol       Date:  2003-09       Impact factor: 4.164

3.  Randomized, controlled trial of RheothRx (poloxamer 188) in patients with suspected acute myocardial infarction. RheothRx in Myocardial Infarction Study Group.

Authors:  C Maynard; R Swenson; J A Paris; J S Martin; A P Hallstrom; M D Cerqueira; W D Weaver
Journal:  Am Heart J       Date:  1998-05       Impact factor: 4.749

4.  Pharmacokinetics of RheothRx injection in healthy male volunteers.

Authors:  R C Jewell; S P Khor; D F Kisor; K A LaCroix; W A Wargin
Journal:  J Pharm Sci       Date:  1997-07       Impact factor: 3.534

5.  Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans.

Authors:  M Depré; E Ehrich; A Van Hecken; I De Lepeleire; A Dallob; P Wong; A Porras; B J Gertz; P J De Schepper
Journal:  Eur J Clin Pharmacol       Date:  2000-05       Impact factor: 2.953

Review 6.  First-time-in-human dose selection: allometric thoughts and perspectives.

Authors:  H Boxenbaum; C DiLea
Journal:  J Clin Pharmacol       Date:  1995-10       Impact factor: 3.126

7.  Limitations of dose tolerance studies on predictability for phase III.

Authors:  S J Warrington
Journal:  Arzneimittelforschung       Date:  1985

8.  Integrated pharmacokinetics and pharmacodynamics of Ro 48-6791, a new benzodiazepine, in comparison with midazolam during first administration to healthy male subjects.

Authors:  J Dingemanse; J M van Gerven; R C Schoemaker; G Roncari; J J Oberyé; M F van Oostenbruggen; J Massarella; P Segala; M Zell; A F Cohen
Journal:  Br J Clin Pharmacol       Date:  1997-11       Impact factor: 4.335

9.  Integrated pharmacokinetics and pharmacodynamics of Ro 48-8684, a new benzodiazepine, in comparison with midazolam during first administration to healthy male subjects.

Authors:  J M van Gerven; G Roncari; R C Schoemaker; J Massarella; P Keesmaat; H Kooyman; P Heizmann; M Zell; A F Cohen; J Dingemanse
Journal:  Br J Clin Pharmacol       Date:  1997-11       Impact factor: 4.335

10.  A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers.

Authors:  H E Greenberg; K Gottesdiener; M Huntington; P Wong; P Larson; L Wildonger; L Gillen; E Dorval; S A Waldman
Journal:  J Clin Pharmacol       Date:  2000-12       Impact factor: 3.126
View more
  11 in total

1.  Testing new drugs in naked apes and getting the dose right in their young.

Authors:  James M Ritter
Journal:  Br J Clin Pharmacol       Date:  2010-10       Impact factor: 4.335

Review 2.  Developing drug prototypes: pharmacology replaces safety and tolerability?

Authors:  Adam F Cohen
Journal:  Nat Rev Drug Discov       Date:  2010-09-17       Impact factor: 84.694

Review 3.  Defining 'signal' and its subtypes in pharmacovigilance based on a systematic review of previous definitions.

Authors:  Manfred Hauben; Jeffrey K Aronson
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

4.  The return of the prodigal son and the extraordinary development route of antibody TGN1412 - lessons for drug development and clinical pharmacology.

Authors:  Marcel J H Kenter; Adam F Cohen
Journal:  Br J Clin Pharmacol       Date:  2015-04       Impact factor: 4.335

5.  Pharmacological vs. classical approaches in the design of first in man clinical drug trials.

Authors:  Cornelis A van den Bogert; Adam F Cohen; Hubert G M Leufkens; Joop M A van Gerven
Journal:  Br J Clin Pharmacol       Date:  2017-10-06       Impact factor: 4.335

6.  Goodbye to all that.

Authors:  Adam Cohen
Journal:  Br J Clin Pharmacol       Date:  2019-12-12       Impact factor: 4.335

7.  Risk assessment in extrapolation of pharmacokinetics from preclinical data to humans.

Authors:  Zvi Teitelbaum; Thierry Lave; Jan Freijer; Adam F Cohen
Journal:  Clin Pharmacokinet       Date:  2010-09       Impact factor: 6.447

8.  Use of pharmacokinetic/ pharmacodynamic modelling for starting dose selection in first-in-human trials of high-risk biologics.

Authors:  Balaji M Agoram
Journal:  Br J Clin Pharmacol       Date:  2008-12-11       Impact factor: 4.335

9.  Implications of the BIA-102474-101 study for review of first-into-human clinical trials.

Authors:  Michael Eddleston; Adam F Cohen; David J Webb
Journal:  Br J Clin Pharmacol       Date:  2016-04       Impact factor: 4.335

10.  The acute effect of beta-guanidinopropionic acid versus creatine or placebo in healthy men (ABC-Trial): A randomized controlled first-in-human trial.

Authors:  Fares A Karamat; Deborah L Horjus; Yentl C Haan; Lisa van der Woude; Marianne C Schaap; Inge Oudman; Gert A van Montfrans; Rienk Nieuwland; Gajja S Salomons; Joseph F Clark; Lizzy M Brewster
Journal:  Br J Clin Pharmacol       Date:  2017-09-20       Impact factor: 4.335
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.